A novel CXCR4 antagonist for hematopoietic stem cell mobilization.

Genzyme Corp., Framingham, MA 01701-9322, USA.
Expert Opinion on Investigational Drugs (Impact Factor: 5.43). 12/2008; 17(11):1749-60. DOI: 10.1517/13543784.17.11.1749
Source: PubMed

ABSTRACT Hematopoietic stem cell (HSC) transplantation is a treatment option for hematological malignancies. Current mobilization regimes frequently result in inadequate numbers of HSC for transplant therefore alternative methods of mobilization are required.
The chemokine receptor CXCR4 and ligand SDF-1 are integrally involved in HSC homing and mobilization. Disruption of the SDF-1/CXCR4 axis by the CXCR4 anatagonist, plerixafor, is shown to improve HSC mobilization.
The molecular and in vivo pharmacology of plerixafor and subsequent clinical development is reviewed.
Preclinical studies demonstrate that plerixafor is a selective antagonist of CXCR4 and can rapidly mobilize HSC. Clinical trials demonstrated improved HSC mobilization when plerixafor was included in the mobilization regimen. These data suggest the potential for a significant role for plerixafor in hematological disease.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Low temperature performance of a 150 W, 50 kHz, 24/48 V boost PWM dc-to-dc converter is reported. The efficiency of the converter using a molypermalloy powder (MPP) core based inductor went up from 94% at room temperature (23 C) to 95.9% at liquid nitrogen temperature (-196 C). A BSCCO based high temperature superconducting (HTS) inductor with a transition temperature of approximately -158 C was compared to a MPP core based inductor in terms of the power converter performance at liquid nitrogen temperature. The use of the HTS inductor in the converter tested yielded no significant performance improvement over the same converter with the MPP inductor. The experimental results are discussed along with the HTS inductor characteristics.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Considering as a lead molecule the chemokine CXCR4 receptor antagonist AMD-3100, which shows significant anti-HIV activity in vitro and in vivo, we investigated a series of structurally related macrocyclic polyamines incorporating o,o'-phenanthroline or 2,2'-bipyridyl scaffolds as potential antiviral agents with lower toxicity and increased activity against both wild type X4-tropic and dual tropic HIV strains. The antiviral activity of these compounds was evaluated by susceptibility assays in PBMC (Peripheral Blood Mononuclear Cells) and compared to that of AMD-3100. The newly investigated compounds showed IC(50)s values in the low micromolar range and significantly inhibited the viral replication of wild type X4-tropic isolate and dual tropic strains. These macrocyclic polyamines constitute a promising class of HIV entry inhibitors.
    Molecules 02/2009; 14(5):1927-37. DOI:10.3390/molecules14051927
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To date, G-CSF is the most favoured cytokine administered for PBSC mobilization because of its great efficacy and lack of serious toxicity. Recently, a pegylated filgrastim (pegfilgrastim) has been introduced. Attachment of the polyethylene glycol (PEG) moiety reduces renal excretion and masks proteolytic cleavage sites resulting in elevated G-CSF serum levels for up to 14 days after a single injection. As single-dose pegfilgrastim had similar effects in the prophylaxis of chemotherapy-induced neutropenia as the daily administration of the unconjugated drug, its capability for the mobilization of haematopoietic stem and progenitor cells has been assessed and presented to be at least equal to that of conventional G-CSF. Administration of pegfilgrastim following high-dose therapy and autologous blood SCT (BSCT) shortened the time to myeloid recovery as seen in conventional G-CSF. Plasma G-CSF levels were about 1 log higher with pegfilgrastim, but in the setting of autologous BSCT this did not translate into a faster haematopoietic recovery. Only few data exist on the biological effects of pegfilgrastim. Still, these data suggest that pegfilgrastim-stimulation results in different functional properties of haematopoietic stem and progenitor cells compared with G-CSF.
    Bone marrow transplantation 04/2009; 43(9):669-77. DOI:10.1038/bmt.2009.59